PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index and Subject index to Volume 12

PERGAMON PRESS · OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1982, U.S. $700.00 including postage and insurance. 2 years, 1982/83, U.S. $1330.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3, 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1981 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 12, 1981, Numbers 1–3

CONTENTS

Number 1

Suicide substrates for mitochondrial enzymes: *T. A. Alston* 1
Substrate interaction with cytochrome P-450: *J. B. Schenkman, S. G. Sligar and D. L. Cinti* 43
Peptides as neurotransmitters: Focus on the enkephalins and endorphins: *R. J. Miller* 73
Concepts basic to pharmacokinetics: *T. N. Tozer* 109
Methods for the evaluation of hydrophobic substrate binding to cytochrome P-450: *W. L. Backes and W. J. Canady* 133
Animal models of Parkinsonism: *E. K. Silbergeld and D. B. Calne* 159
An overview of toxin–receptor interactions: *H. Le Vine and P. Cuatrecasas* 167
ACTH-induced excessive grooming in the rat: *W. H. Gispen and R. L. Isaacson* 209

Number 2

Assay of estrogens: *G. E. Abraham and B. N. Saxena* 247
Viral chemotherapy: Antiviral actions of metal ions and metal-chelating agents: *D. D. Perrin and H. Stunzi* 255
Excretion of drugs during postnatal development: *H. Bräunlich* 299
Opiocortin peptides: Localization, source and avenues of transport: *E. R. de Kloet, M. Palkovits and E. Mezey* 321
Effects of ACTH and related peptides on cerebral RNA and protein synthesis: *A. J. Dunn and P. Schotman* 353
The pain relief clinic: *M. Mehta* 373
Clinical aspects of photochemo-therapy: *C. Wolf and H. Honigsmann* 381
Beta-adrenoceptor antagonists in psychiatry and neurology: *D. N. Middlemiss, D. A. Buxton and D. T. Greenwood* 419

Number 3

Antiestrogens: *P. K. Devi* 439
Breakdown and fate of ACTH and MSH: *M. E. A. Reith and A. Neidle* 449
Neuropeptides and brain cAMP and phosphoproteins: *V. M. Wiegant, H. Zwiers and W. H. Gispen* 463
Properties and pharmacological action of plague murine toxin: *T. C. Montie* 491
Anthrax toxin: *J. Stephen* 501
Transport of nucleoside drugs in animal cells: *A. R. P. Paterson, N. Kolassa and C. E. Cass* 515
History of pharmacokinetics: *J. G. Wagner* 537
Patients' experience of pain: *M. R. Bond* 563
Analgesic drugs: *K. Budd* 575
Assessment of analgesic drugs: *J. W. Dundee and W. B. Loan* 589
Neurolytic and other locally-acting drugs in the management of pain: *F. Wilson* 599
Impairment of glucose tolerance produced by diuretics and other drugs: *B. L. Furman* 613

AUTHOR INDEX

Abraham, G. E. 247
Alston, T. A. 1

Backes, W. L. 133
Bond, M. R. 563
Bräunlich, H. 299
Budd, K. 575
Buxton, D. A. 419

Calne, D. B. 159
Canady, W. K. 133
Cass, C. E. 515
Cinti, D. L. 43
Cuatrecasas, P. 167

De Kloet, E. R. 321
Devi, P. K. 439
Dundee, J. W. 589
Dunn, A. J. 353

Furman, B. L. 613

Gispen, W. H. 209, 463
Greenwood, D. T. 419

Honigsmann, H. 381

Isaacson, R. L. 209

Kolassa, N. 515

Le Vine, H. 167
Loan, W. B. 589

Mehta, M. 373
Mezey, E. 321
Miller, R. J. 73
Middlemiss, D. N. 419
Montie, T. C. 491

Neidle, A. 449

Palkovits, M. 321
Paterson, A. R. P. 515
Perrin, D. D. 255

Reith, M. E. A. 449

Saxena, B. N. 247
Schenkman, J. B. 43
Schotman, P. 353
Silbergeld, E. K. 159
Sligar, S. G. 43
Stephen, J. 501
Stunzi, H. 255

Tozer, T. N. 109

Wagner, J. G. 537
Wiegant, V. M. 463
Wilson, F. 599
Wolf, C. 381

Zwiers, H. 463

SUBJECT INDEX

Abrin
  binding and penetration 181, 182
  properties 180, 181
  receptor moiety 182–4
  site of action 181
  toxin fragment role 182
Acetaldehyde oxidation 14
Acyl transferases 17
adenine arabinoside 29
S-adenosylhomocystine hydrolase, suicide inactivators 29
β-adrenoceptor antagonists
  in anxiety 422
  chemical structure 420
  in migraine 423
  pharmacological activity 420
  in psychiatry and neurology 419–31
  schizophrenia and mania 423, 424
  in tremor 423
β-adrenoceptor blockers, glucose tolerance 621, 622
β-adrenoceptors
  CNS, evidence for 425, 426
  neuropharmacological effects 426–31
  receptor interaction 430
Adrenocorticotrophic hormone (ACTH) 77, 101, 333, 334
  adrenal breakdown 452, 453
  amino acid sequence 226
  analog metabolism 456, 457
  brain action, model 481, 482
  brain metabolism 453, 454
  and brain phosphoproteins 229, 230
  and cell free protein synthesis 363, 364
  and cerebral RNA and protein synthesis 353–69
  degradation mechanism 454, 455
  effects on grooming 216, 217
  effects on plasma corticosteroids and grooming 224, 225
  effects on specific proteins 365, 366
  endogenous, inactivation 450, 451
  endopeptidase action 458
  excessive grooming in rats 209–41
  exopeptidase action 457
  fragment size and metabolism 454
  half-life 449–51
  and hypophysectomy 358, 359
  icv effects in rat 215–19
  -induced grooming, tolerance 235, 236
  intestinal metabolism 453
  and membrane phospholipid phosphorylation 481, 482
  metabolism 451–5
  modes of action 368
  and neuropeptide action 473–7
  opiate interaction 230–3
  and pineal protein synthesis 361–3
  pituitary metabolism 453
  polyribosomal aggregation 359–65
  -positive cells 323
  and RNA labelling 355, 356
  and SPM protein phosphorylation 477–9
  structure-activity studies and grooming 225–30
Adriamycin 283, 284
Age
  and chemotherapeutic efficacy 313
  and xenobiotic nephrotoxicity 309, 310
Albizziin 13
Aldehyde dehydrogenases, suicide substrates 13–15
Aliin 11
Alizarin Red S 281, 282
3-alkynoyl thioesters 17
D-amino acid oxidase inactivation 4
Amino acids
  β, γ-olefinic 8
  reactive leaving groups 11
1-aminoadamantane (amantidine) 284
β-aminobenzaldehyde thiosemicarbazone 255
2-amino-4-methoxy-*trans*-2-butenoate, suicide substrate 9
Aminopyrine and cytochrome P-450 spin state 58
Amobarbital, plasma concentration–time data 542, 543
AMP, cyclic
  effect of ACTH and MSH on brain 473–5
  and neuropeptides 463–83
  proposed role 472
  second messenger model 464, 465
  structure 464
Analgesic assessment 589–96
  bias control 591
  drug administration 590, 591
  methods 594
  pain measurement 592
  pain nature 590
  standardization 589–91
Analgesics 575–86
  action 577
  administration 577, 578
  agonists 580–2
  antagonists 582
  centrally acting 576
  ineffective 579
  interaction 579
  local 601, 602
  low potency 583–6
  mode of action 582, 583
  peripherally acting 576
  potent 580–3
  potency 576, 577
  and prostaglandin synthesis 586
  side-effects 578, 595, 602
Animals, effect of ergot derivatives 162–4
Animal models of parkinsonism 159–65
  basis 159
Anthrax toxin 501–12
  complexity 504
  discovery 502–5
  experimental guinea-pig 502, 503
  isolation 504
  and pathogenesis 505, 506
  pathophysiology 506–10
  properties 511
  terminal bacteraemia 503, 504
Antiestrogens 439–45
  chemistry 439, 440
  clinical use 441–4

definition 439
evaluation 440
mode of action 440, 441
Arsenicals, reactions of 2
Aspartate aminotransferase, reactions catalysed 7
Assays
estrogen 247–52
steps in typical 248
Atenolol, brain radioactivity 421
5-azacytidine 524

Behaviour, response to novel cage 215
Behaviour tests, ergot derivatives 163
Benzphetamine and cytochrome P-450 spin equilibrium 58
Bioassay, opiate-sensitive 97
Biological fluids 248
Bis(glycinato)copper II complex 258
Bombesin 101
Brain
access to 419–21
ACTH action, model 482
kinases 471
Bromocriptine 163

Calcium
antagonists 637
proposed action in neurotransmission 472
second messenger 466
Cataracts and PUVA 402
Cells
nucleoside transport 520
nucleoside transport inhibition protection 526, 527
Centchroman, clinical use 441
Chemophotochemotherapy 410, 411
Chloral hydrate 14
Cholecystokinin (CCK) 101
Chromatography
adsorption column 249, 250
column partition 249
gas–liquid, partition 250
Clomiphene citrate
clinical use 441, 442
dose 442
side effects 442
Clonidine and glucose tolerance 623
Clostridium botulinum type A toxin
binding and intoxication 188, 189
properties 188
receptor moiety 189, 190
Clostridium tetani toxin 184–8
binding and penetration 186, 187
intracellular intoxication 185, 186
properties 184, 185
retrograde axonal transport 187, 188
Complex formation 257, 258
Coprine 14
Corticotropin-like intermediate lobe peptide (CLIP) 77
Corynebacterium diphtheriae exotoxin 171–8
binding and penetration 172–5
fragment role 175–7
intracellular intoxication 172
properties 171
receptor moiety 177, 178
Countercurrent distribution 249
3-cyanoalanine 9
4-cyano-GABA 24
Cyanoketone 26
Cyclic nucleotides *see also* AMP, GMP
neurotransmission action 473–7
subcellular localization 466
N-cyclopropylbenzylamine 20
N-cyclopropyltryptamine 20
Cycloserine 24
Cyproheptadine and glucose tolerance 636
Cystamine 268, 269
Cytochrome P-450
binding thermodynamics 153–6
dual substrate interactions 139–47
heme iron and spin state 53–6
hydrophobic substance binding 133–57
lipid binding and spin state 62, 63
lipid faced sides 152
membrane effect on function 63, 64
microsomal membrane and binding site orientation 151–3
naphthalene binding and solubility 150
non-specific solvent effects 147–51
oxidized, binding 134, 135
phenacetin bound temperature sensitivity 59
redox potential and spin state 64–7
solvent interactions 138–47
spectral changes 44–53
spin state and temperature 56–60
substrate binding, thermodynamic model 60–2
substrate interaction 43–67
Cytosine arabinoside 524
Cytotoxic agents 31, 32

Dale's principle 91
Daunomycin 283, 284
2-deoxyadenine 29
5′-deoxyadenosine 524
Diazepam, volume of distribution and age 129
O-diazoacetylserine 13
6-diazo-5-oxonorvaline 13
Diazoxide
and glucose tolerance 619–21
hyperglycaemia 620, 621
Dichlorovinylcysteine 11
Diethylstilbestrol 26
β-diketones, antiviral activity 280, 281
N, N-dimethylglycinedehydrogenase inactivation 29
Disulfiram 14
Diuretics
and carbohydrate metabolism 615, 616
and glucose tolerance 613–19
and glucose utilization 619
and insulin secretion 618, 619
renal effects 617
DNA cross linking agents 32
Dopamine and grooming behaviour 236–8
Drug excretion
extrarenal 299
postnatal 299–313
renal 299
renal and age 306–9
Drugs
analgesic 575–85, 589–96
antidepressant and pain 571, 572
antihypertensive and glucose tolerance 613–19
antiviral, mode of action 266
anxiolytic and pain 570, 571
clearance and volume of distribution 125
diuretics, age effect 312
hepatic extraction ratio 120
neuroleptic and glucose tolerance 635
neuroleptic and pain 571
neurolytic 599–610
nucleoside, transport 522–9
Dynorphin 480, 481

Endorphin 77, 332, 333
amino acid sequence 226
antagonists 98, 99

brain 326
and brain AMP 475–7
grooming induction 230–3
kitten pituitary immunoreactivity 92
pituitary 325
and SPM protein phosphorylation 480, 481
stability 95
Enkephalins 77, 326–31
antagonists 98
biosynthesis 93–7
brain 326
and brain AMP 475–7
CNS distribution 81–8
duodenum immunoreactivity 90
inactivation 94
medulla, ultrastructural localization 88
neurochemistry 93–7
peripheral nervous system localization 89–91
pituitary 325
rat brain immunoreactivity 83, 84
rat caudate immunoreactivity, electron micrographs 86, 87
and SPM protein phosphorylation 480, 481
stability 95
Enzyme–inhibitor complex formation, partition model 135, 136
Enzymes
action on ACTH 457, 458
inhibition of viral 267–87
not used by healthy cells 265
Ergot derivatives
behavioural effects 163
structures 162
Escherichia coli heat labile enterotoxin
binding and penetration 197
properties 196
Escherichia coli heat stable enterotoxin 195, 196
Estrogen assays 247–52
Estrogens
biological definition 247
detection methods 250–2
extraction 248, 249
purification methods 249, 250
radioisotopic detection 251, 252
Ethanol
effect on rats and ethylbenzene 144
naphthalene binding to cytochrome P-450 150
Ethanolamine-*O*-sulfate 24
Ethylbenzene, cytochrome P-450 association 138
Ethylene diamine tetracetic acid (EDTA) 268, 282
Ethylene glycol-bis-(β-aminoethylether)-N, N, N′, N′-tetracetate (EGTA) 268
4-ethynyl-GABA 24
Etorphine, binding capacity of brain regions 79

Fatty acids, inhibitors of catabolism 16–19
Ferricytochrome P-450, electron paramagnetic resonance 55
Flavinoids, viral inhibition 281, 282
Flavins from acetylenic suicide substrates 15
3-fluoro-D-alanine 29
5-fluorodeoxyuridylate 29
2-formyl-3-hyroxy-4, 5-*bis* (hydroxymethyl) pyridine thiosemicarbazone 273
2-formylpyridine thiophosphorus hydrazones 275
2-formylpyridine thiosemicarbazone 269
Free fatty acids, metabolism and plague toxin 493, 494

Gabaculine 24
GABA transaminase inactivation 23–5
Glucose tolerance
drug induced impairment 613–39
drugs affecting 638
and insulin secretion and estrogens and progestogens 631, 632
Glutamine antagonists 29
Glutamine hydrolase inhibitors 12, 13
Glutamine synthetase inhibition 12, 13
GMP, cyclic, second messenger 465, 466
Grooming behaviour 209–13
ACTH induced 209–41
and acute tolerance 235, 236
body 210
and brain lesions 233–5
and brain phosphoproteins 229, 230
dopamine involvement 236–8
endocrine independence 223–5
endorphin induction 230–3
face washing 230
genitals 210
and hypophysectomy 222, 223
noradrenaline involvement 238, 239
paws 211
peptide-induced, nature 213, 214
in rat 209–13
and stress 220–2
structure-activity study of ACTH 225–9
types after icv ACTH 216, 217

Heme iron
energy level diagram 53
spin state 53–5
Hemoproteins, reactions 43
Hexobarbital
and cytochrome P-450 spectral change 53
and cytochrome P-450 spin equilibrium 58
3-hydroxydecanoyl thioester dehydrase inactivation 17
8-hydroxyquinoline 267, 268, 282, 283
Hypoglycin 17
Hypophysectomy
and cerebral protein synthesis 356, 357
and grooming in rats 222, 223

Iminium-trapping agents 4
Inhibitors
cytotoxic agents 31, 32
fatty acid catabolism 16–19
Krebs' cycle 1–6
Krebs' cycle accessory enzymes 7–16
neurotransmitter metabolism 19–25
nucleoside transport 521, 526, 527
one-carbon unit metabolism 28–31
partition model of enzyme complex formation 137, 138
pyruvate dehydrogenase 1–6
steroid metabolism 25–8
transaminases 7–16
Iproniazid, monoamine oxidase inhibition 20
Isatin-β-thiosemicarbazone 270
contact inhibition 277, 278
N-ethyl-*S*-butyl virus inhibition 277
N-substituted, terdentate ligand 276
and pox virus 275–7
Isogabaculine 24
Isoniazid 283
Isoproterenol 496

Kethoxal bisthiosemicarbazone 271, 272
anticancer 272
Ketosteroid isomerase inhibitor 26
Kidney
drug efficacy and age 312, 313
drug excretion and age 306–9
postnatal maturation of function 300–5
sodium excretion and load 304

tubular transport stimulation and age 310, 311
uranyl nitrate damage 303
Kojic acid 281, 282
Krebs' cycle
accessory enzymes, inhibitors 7–16
inhibitors 1–6

Lactate oxidizing flavoenzymes, suicide substrates 15, 16
Lergotrile 163
Liposome
and drug delivery 288, 289
formation 287, 288
Lipotropin 77, 331, 332
amino acid sequence 226
fragments 475
Lisuride 163

M & B 7714 270
Melanocyte stimulating hormone (MSH) 77, 101, 334–6
amino acid sequences 226
breakdown 455
6-mercaptopurine arabinoside 524
2-mercapto-1-(β-4-pyridethyl)-benzimidazole 283
Metal ions
in biological systems 256–63
complex, stability constants 258, 259
hard and soft 260
pM and buffers 260, 261
Metergoline 163
Methionine sulfoximine 13
Methoxsalen 381
5-methoxypsoralen 411, 412
structure 411
8-methoxypsoralen, structure 383
3-methylcholanthrene 55
1-methylisatin-β-thiosemicarbazone and smallpox 256
Methyl *ortho*-formylbenzoate 14
Microtubule inhibitors 636, 637
Migraine 423
Mitochondrial enzymes, suicide substrates 1–33
Mitomycin C, aziridinyl group reactivity 32
Mitotane 26
Modeccin
binding and penetration 181, 182
properties 180, 181
receptor moiety 182–4
site of action 181
toxin fragment role 182
Monoamine oxidase inhibitors 19–23

Nafoxidine hydrochloride 444
Naloxone 98, 99
Naltrexone 98, 99
Nerve blocks 602–10
alcohol 603
chlorocresol 603
coeliac plexus 607–9
indications 603, 604
intercostal 603
intervertebral spaces 604, 605
lumbar sympathectomy 609
phenol 602
priapism 609, 610
vaginal vault cancer 609
Neurolytic drugs
cancer pain 604–6
fractures 606, 607
pain management 599–610
Neurotensin 101
Neurotransmitters
cyclic nucleotide mediation 466–8
metabolism inhibition 19–25
opioid peptide role 99–101, 473–7
peptide 73–101
Nitrofurantoin, renal excretion and urine pH 307
Nitrogen mustards, enzymically activated 21
Noradrenaline and grooming behaviour 238, 239
Norethindrone 26
Novel glass box 215
Nucleoside
analogs and nucleoside uptake 528, 529
analogs and transport parameters 524–9
kinetic data and cellular uptake 532–4
structural formulae 534–6
transport inhibitor, cell protection 526, 527
and uridine cell efflux 528
Nucleoside drugs
kinetics of transport 516–18
measurement of transport 518, 519
physiological transport 519–21
transport criteria 522
transporter-mediated permeation 522–9
transport inhibitors 521, 523
transport and metabolism 515, 516

Oestrogens *see also* estrogens
and carbohydrate metabolism 630, 631
and glucose tolerance 623–8, 631
and insulin secretion 631, 632
secretion of growth hormone 632
Oncogenic effects of PUVA 407–9
One carbon unit metabolism inhibitors 28–31
Opiate receptors 77–81
brain, etorphine binding 79, 80
localization and function 80, 81
properties 77, 78
Opiates, tolerance in cell culture 476, 477
Opiocortin peptides 321–45
brain 325–36
brain and hypophysectomy 336
control of synthesis and release 325
in vitro brain synthesis 337, 338
in median eminence 340, 341
neural, origin 321–3
neural source 336–8
pituitary 323
pituitary source 338–43
rat brain concentrations 328, 329
synthesis and transport 336, 337
Opium constituents 575
Oral contraceptives
altered tryptophan metabolism 633
glucagon secretion 633
glucocorticoids 632, 633
growth hormone secretion 632
mixture 626, 627, 629
oestrogen 624, 628
progestogen 625, 626, 628, 629
and vitamin B_6 metabolism 634
3-oxoacyl CoA thiolase inactivation 17

Pain
arachnoid 601
assessment 564, 565, 592–4
cancer 605, 606
chronic treatment of 374
components 373
consequences, psychosocial and social 569, 570
nature 563, 564
neurolytic, management 599–610
patients' experience 563–72
and personality 565–9
psychotropic drugs 570–2
types 599–601

Pain relief clinic 373–80
aims 374, 375
cases referred 375
development 380
and diagnosis 374
evaluation of techniques 375
evolution 373
in-patients 377, 378
organization 375–7
out-patients 377
personnel 378, 379
Pargyline 20, 22
Parkinsonism
animals 159–65
ergot derivatives, effects 162–4
substantia nigra lesion 160
Penicillamine 268, 269
4-pentenoate catabolism 17
Peptide neurotransmitters 73–101 *see also* endorphin, enkephalin
Peptides
opiocortin 321–45
opioid, discovery 76
nervous and gastrointestinal 74
Pharmacokinetics 109–30, 537–53
amobarbital 542
apparant volumes 111, 112
availability 123
binding changes, effects 114, 115
bioavailability 551, 552
blood sampling 109, 110
books concerned with 542, 545
cancer chemotherapy 547
clearance, factors affecting 129, 130
clearance terms 118–22
clinical 552, 553
and computers 551
definition 109, 537
drug distribution model 112, 113
drug interactions 552
elimination 118–22
excreta analysis 110
factors affecting values 127–30
first-pass effect 120, 123
hepatic clearance 122
factors affecting 130
hepatic extraction ratio and drugs 120
history 537–53
intrinsic clearance 120, 123
linear binding 547, 548
mass balance 119
model independent methods 549–51
models 545–9
multicompartment distribution 115–18
multicompartment models 124
nonlinear 548
one compartment model 124
origins 537
parameters 110, 111
plasma clearance 122
plasma protein binding reduction 127
plasma protein and tissue binding 112–14, 124–7
proportionality constants 118
propranolol 116–28
rate constants 124–7
and plasma protein and tissue binding 124–7
renal clearance and factors affecting 130
steady state concentration 540
time changes 115–18
volume of distribution 114–18
and age 129
factors affecting 127–9
Phenacetin 59
and cytochrome P-450 spin equilibrium 58
1, 10-phenanthroline 267
Phenelzine 20
Phenobarbital, effects on cytochrome P-450 in rats 145
Phenytoin and glucose tolerance 634, 635
Phosphonoacetic acid, viral inhibition 278–80
Phosphoproteins 468
and neurotransmission 472, 473
second messengers 469, 470
Photochemotherapy (PUVA)
clearing phase 390–6
clinical aspects 381–413
contraindications 401
drugs 383, 384
improvements 409–12
long-term risks 401–9
maintenance therapy 390, 396–9
oncogenic effects 407–9
patient sensitivity 386
phototoxic reactions 385, 386
principles of 382–8
and psoriasis 390–9
side effects 399–401
skin structure 382
skin types 387
treatment methods 388–90
and UV-A 384, 385
Photosensitivity-pigmentation index 368
Phototoxicity testing 387, 388
Pineal, protein synthesis modulation 363
Pituitary
and brain opiocortins 338–43
opioids 325
Pizotifen 636
Plague murine toxin 491–8
and β-adrenergic blockers 496, 497
chemistry 492, 493
composition 491, 492
and free fatty acid metabolism 493, 494
metabolic activity 493
mode of action 493, 494
pM 260
Polyribosomal aggregation 359–65
Prazosin and glucose tolerance 623
Progestogens
and carbohydrate metabolism 630, 631
glucose intolerance 623–31
and growth hormone secretion 632
and insulin secretion 631, 632
Pro-opiocortin related peptides, distribution 91–3
Propargylglycine 10
Propranolol
brain distribution 421
fraction unbound and disease 128
and hyperactivity 430
volume of distribution 116
Prostaglandins, synthesis pathways 586
Protein synthesis
brain slices 360, 361
cell-free slices 362–4
cerebral ACTH effect 353–69
non-NAD dependent inhibition by toxins 180–4
pineal and ACTH 361, 362
Pseudomonas aeruginosa exoenzyme S 180
Pseudomonas aeruginosa exotoxin A
binding and penetration 179, 180
properties 178, 179
Psoriasis
erythroderma 394, 395
palmar 392
pustular 395
PUVA treatment 390–9

PUVA 381 *see also* photochemotherapy
-induced mottling 405–7
Pyruvate dehydrogenase
inhibitors 1–6
2-ketobutyrate inactivation 6

Radioimmunoassay
estrogen 252
opiocortins 326
Rat
ACTH-induced grooming 209–41
furless 213
response to novel glass box 215
stretching and yawning 218–20
Receptors
abrin, modeccin and ricin 182–4
β-adreno in CNS 425, 426
Clostridium botulinum toxin 189, 190
Corynebacterium diphtheriae exotoxin 177, 178
opiate 77–81
toxin and normal action 197–9
Vibrio cholerae toxin 193–5
Ricin
binding and penetration 181, 182
properties 180, 181
receptor moiety 182–4
site of action 181
toxin fragment role 182
Rifamycin 284
RNA, ACTH effects 354–6
RNA synthesis, cerebral and ACTH 353–69

Sarcosine dehydrogenase inhibitors 29
Second messengers 464–6
Selenocystamine 269
Selenocystine 282
Serine hydroxymethylase inactivation 29
Serine-*O*-sulfate, suicide substrate 9
Skin degeneration and PUVA 402–5
Solvent and cytochrome P-450 interactions 138–47
Spectral changes of cytochrome P-450 44–53
reverse type 1 and alcohols 49
substrate reversibility 50
type I 44
type I, agents inducing 45–8
type II 45
type II, agents inducing 51, 52
Spironolactone 26
Staphylococcal leukocidin, properties 169
Staphylococcal α-toxin, properties 169
Steroid metabolism, inhibitors 25–8
Steroids, estrogenic activity 247
Streptolysin O, properties 168, 169
Stress
and brain protein synthesis 358, 359
and grooming in rats 220–2
Stretching and yawning syndrome 218–20
Substance P 98
neurotransmission 100, 101
Substantia nigra, consequences of lesion 160
Succinate dehydrogenase, 3-nitropropionic acid inhibition 4
Suicide substrates
glutamine analogues 13
mitochondrial enzymes 1–33

Tabtoxinine-β-lactam 13
Tamoxifine
clinical studies 443
dose 443
side effects 443, 444
Temperature and spin state of cytochrome P-450 56–60
Thiosemicarbazones
α-(N)-heterocyclic 273–5
bis- 271, 272
iron complex 274
metal binding 271
and viral chemotherapy 270–8
Thymidylate synthetase, suicide inactivators 29
Toxin–receptor interactions 167–99
Toxins
anthrax 501–12
cytolytic 168–70
cytotoxic 170–84
entero- 190–7
enzymatic 170
nervous system, bacterial 184–90
non-thiol 169, 170
plague 491–9
receptors 197–9
surfactants 168
thiol activated 168, 169
Transaminases
inactivation 9
inhibitors 7–12
reactions catalysed 8
Tranylcypromine 20
5-trifluoromethyldeoxyuridylate 29
Tryptophan metabolism and oral contraception 633

Ultraviolet, skin penetration 385 *see also* photochemotherapy

Vaginal changes and estrogen detection 250, 251
Vasointestinal polypeptide 101
Vasopressin 73
Vibrio cholerae enterotoxin
binding and penetration 191–3
intoxication process 191
properties 190
receptor moiety 193–5
solubilization 194
4-vinyl GABA 24
Viral chemotherapy 255–89
chelating agents 280–3
liposome delivery 287–9
metal ion manipulation 284–6
mode of action of agents 266, 267
thiosemicarbazones 270–8
Virus
DNA 263
enzyme inhibition 267–87
host interaction 263–7
interference with replication 265–7
replication cycle 263–5
RNA 263

Warfarin, plasma clearance 122

Xenobiotics, nephrotoxicity and age 309, 310

Zinc
effects on virus 284, 285
in polymerases 257

Pharmac. Ther. Vol. 12.
© Pergamon Press Ltd. 1981. Printed in Great Britain.

ERRATUM TO:

Glucose Analogues in the Chemotherapy of Herpesvirus Infections

by Herbert A. Blough and Eva K. Ray

Pharmacology and Therapeutics, Vol. 10, No. 3 (1980) pp. 669-681.

On page 679 of the above article, the final paragraph was misprinted, with certain material missing. This paragraph should read:

> From these fundamental and clinical studies, it appears that dGlc has unique potential as a rotational and effective chemotherapeutic agent in the treatment of genital herpes. It prevents the synthesis and elongation of oligosaccharide chains required for viral envolope biogenesis and recognition phenomena may be absent since receptor molecules may not be synthesized. Further, dGlc is relatively non-toxic, and penetrates readily into most tissues (although this may be the function of the vehicle). We believe it to possess unique potential as a chemotherapeutic agent in the treatment of both ocular and genital herpes. dGlc can potentially be administered systemically for generalized herpesviremia and/or encephalitis. There is much progress to be made in the years ahead in attempts to develop additional sugar analogues which could have comparable antiviral activity. One of the mainstays of antiviral chemotherapy is that the agents used do not effect host cell macromolecular synthesis; it appears evident that this may have to be modified to include agents such as dGlc, which appears to have little or no cytotoxicity, and upon removal of the drug, the glycoslytransferases and normal mechanisms for chain elongation of oligosaccharides appear to be renewed.

Pharmac. Ther. Vol. 12, p. i
Pergamon Press Ltd. Printed in Great Britain

ERRATUM

Pharmacology and Therapeutics, Volume 11, Number 3.

The publishers wish to apologise for the misspelling of Dr. Friedrich Dorner's name on page 661 of Dr. Joseph Alouf's article "Streptoccal toxins (Streptolysin O, streptolysin E, erythogenic toxin)".